Pfizer Halts Weight-Loss Pill Development After Liver Injury | JQJO

Pfizer halted development of its experimental daily weight-loss pill, danuglipron, following a patient's potential liver injury in a trial. The patient's liver enzymes recovered, but the incident, coupled with previous setbacks, led Pfizer to discontinue the drug. While disappointed, Pfizer remains committed to its other weight-loss drug development programs, aiming for a share of the burgeoning GLP-1 market, estimated to reach over $150 billion by the early 2030s. This setback follows the discontinuation of a twice-daily version and another obesity pill last year. Despite this, Pfizer highlighted positive findings from recent studies on danuglipron and emphasized its ongoing commitment to obesity treatment.